Orphan Drugs Market By Therapy (Oncology, Neurology, Endocrinology, Hematology, Cardiovascular, Immunotherapy, Respiratory, and Other Therapies), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Sep 2024
- Report ID: 84896
- Number of Pages: 277
- Format:
-
-
-
- Hoffmann-La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- Johnson & Johnson Services Inc. (U.S.)
- Merck KGaA (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Pfizer Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Novo Nordisk A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Kyowa Kirin Co., Ltd. (Japan)
- GlaxoSmithKline Plc
- AbbVie Inc. Company Profile
- Sanofi S.A
- Amgen Inc. (U.S.)
- Biogen Inc. (U.S.)
- Celldex Therapeutics (U.S.)
- GSK plc. (U.K.)
- Eisai Co., Ltd. (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- Alexion Pharmaceutical Inc.
- ALX Oncology Holdings Inc.
- BioMarin Pharmaceutical Inc.
- Agios Pharmaceuticals Inc.
- DAIICHI SANKYO Company Ltd.
- Other Key Players
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |